対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第1章	予　防

第1節	インターフェロン療法
CQ1	インターフェロンは，C型慢性肝疾患からの発癌予防に有効か？
[PubMed]	
#1	"Liver Neoplasms"[MH] AND "Interferons"[majr] AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Liver Neoplasms"[MH] AND "Interferons"[majr] AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

第2節	肝庇護療法
CQ2	肝庇護療法は肝細胞癌の発癌予防に有効か？
[PubMed]	
#1	"Carcinoma, Hepatocellular/prevention and control"[MH] AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Carcinoma, Hepatocellular/prevention and control"[MH] AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

CQ3	B型慢性肝疾患に対する抗ウイルス療法は肝細胞癌の発癌予防に有効か？
[PubMed]	
#1	"Liver Neoplasms"[MH] AND ("lamivudine" [tiab] OR "adefovir dipivoxil" [Supplementary Concept] OR adefovir[tiab] OR "tenofovir disoproxil" [Supplementary Concept] OR tenofovir[tiab] OR "entecavir" [Supplementary Concept] OR entecavir[tiab] OR 3TC[tiab] OR emtricitabine [Supplementary Concept] OR emtricitabine[tiab]) AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT
#2	"Liver Neoplasms"[MH] AND ("lamivudine" [tiab] OR "adefovir dipivoxil" [Supplementary Concept] OR adefovir[tiab] OR "tenofovir disoproxil" [Supplementary Concept] OR tenofovir[tiab] OR "entecavir" [Supplementary Concept] OR entecavir[tiab] OR 3TC[tiab] OR emtricitabine [Supplementary Concept] OR emtricitabine[tiab]) AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第2章	診断およびサーベイランス

第1節	サーベイランス
CQ4	サーベイランスは，どのような対象に行うか？
[PubMed]	
#1	"Risk Factors"[MH] "Carcinoma, Hepatocellular"[majr] AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Risk Factors"[MH] "Carcinoma, Hepatocellular"[majr] AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

CQ5	サーベイランスは，予後を改善するか？
CQ6	サーベイランスは，どのような方法で行うか？
[PubMed]	
#1	"Liver Neoplasms"[MH] AND (surveillance[tiab] OR screening[tiab]) AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Liver Neoplasms"[MH] AND (surveillance[tiab] OR screening[tiab]) AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

CQ7	Dynamic CT／MRIで典型的所見を示さない肝結節の精査は，何cm以上から行うのが望ましいか？
[PubMed]	
#1	"Liver Neoplasms" [MH] AND (biopsy[MH] OR hepatectomy[MH] OR pathology[MH] OR patholo*[tiab] OR resection*[tiab]) AND ("MRI"[tiab] OR "CT"[tiab] OR ultraso*[tiab]) AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Liver Neoplasms" [MH] AND (biopsy[MH] OR hepatectomy[MH] OR pathology[MH] OR patholo*[tiab] OR resection*[tiab]) AND ("MRI"[tiab] OR "CT"[tiab] OR ultraso*[tiab]) AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

第2節	腫瘍マーカー
CQ8	肝細胞癌の診断において2種以上の腫瘍マーカーを測定することは有用か？
[PubMed]	
#1	"Liver Neoplasms"[MH] AND "sensitivity and specificity"[MH] AND ("AFP"[tiab] OR "alphaf*"[tiab] OR "DCP"[tiab] OR des-gamma*[tiab] OR desgamma*[tiab] OR PIVKA*[tiab] OR Glypican-3[tiab] OR GP3[tiab] OR "Tumor Markers, Biological"[MH]) AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Liver Neoplasms"[MH] AND "sensitivity and specificity"[MH] AND ("AFP"[tiab] OR alphaf*[tiab] OR "DCP"[tiab] OR des-gamma*[tiab] OR desgamma*[tiab] OR PIVKA*[tiab] OR Glypican-3[tiab] OR GP3[tiab] OR "Tumor Markers, Biological"[MH]) AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

CQ9	腫瘍マーカーの測定は，肝細胞癌の治療後の指標として有効か？
[PubMed]	
#1	"Liver Neoplasms/therapy"[majr] AND ("AFP"[tiab] OR alphaf*[tiab] OR "DCP"[tiab] OR des-gamma*[tiab] OR desgamma*[tiab] OR PIVKA*[tiab] OR "Tumor Markers, Biological"[MH]) AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	"Liver Neoplasms/therapy"[majr] AND ("AFP"[tiab] OR alphaf*[tiab] OR "DCP"[tiab] OR des-gamma*[tiab] OR desgamma*[tiab] OR PIVKA*[tiab] OR "Tumor Markers, Biological"[MH]) AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

第3節	画像診断
CQ10	肝硬変患者における早期肝細胞癌の検出において，診断能が高い検査は何か？
[MEDLINE]	
S1	LIVER CIRRHOSIS! OR (LIVER OR LIVERS OR HEPATIC)(3N)CIRRHO? OR CHRONIC?(3N)LIVER(2W)(DISEASE? OR DISORDER?)
S2	(WELL()DIFFERENTI? OR SMALL? OR HYPOVASCULAR? OR ADENOMATOUS?(3N)HYPERPLASI? OR DYSPLASTI?(3N)NODUL?)/TI
S3	(BORDERLIN? OR NODUL?)/TI
S4	INTERNATIONAL?(3N)CONSENS?(3N)GROUP?(3N)HEPATOCEL?()NEOPLAS?
S5	FOCAL NODULAR HYPERPLASIA!

S6	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S7	EARLY(4N)(CARCINOM? OR HCC OR HEPATOM? OR NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR HAEPATOM? OR HCCS)
S8	DISEASE PROGRESSION!
S9	DI/DE OR US/DE OR RA/DE OR RI/DE OR DIAGNOSTIC IMAGING!
S10	CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING?
S11	OUTCOME?/TI
S12	SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC
S13	(S1/DE OR S1/TI OR S2 OR S3 OR S4 OR S5)*(S6+S7+S8)*(S9+S10)
S14	S13*(LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?)/TI AND S11
S15	(DIAGNOS? OR IDENTI? OR DETECT? OR ASSESS? OR EVALUAT? OR MANAGE?)/TI
S16	(LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?)/TI AND S13 AND (S15+S10/TI)
S17	S16*S12
S18	S17+S14
S19	S18/HUMAN+(S18 NOT ANIMALS)
S20	S19/ENG
S21	S20 AND PY=>1982 AND UP=19830906:20111231

CQ11	**肝細胞癌の高危険群において，典型的肝細胞癌の診断に診断能が高い検査は何か？**
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	(DI+DIAGNOSIS!+RA+RI+US)/DF+(DIAGNOS? OR DETECT? OR IDENTI?OR TEST? OR IMAG?)/TI
S6	SENSITIVIT?+SPECIFICIT?+ACCURAC?
S7	S4*S5*S6
S8	(USEFUL? OR EFFICAC? OR EFFECTIV?)/TI
S9	MT/DE
S10	S7*S8*S9
S11	S7*S8+S7*S9

CQ12	**肝細胞癌の治療前検査として血管造影は必要か？**
CQ13	**肝細胞癌の治療前検査としてCTAP／CTHAは必要か？**
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG

S15	S14 AND UP=20070701:20111231
S16	PREEXAMINAT?+PRE(1W)EXAMINAT?+PREDIAGNOS?+PRETREATMENT?+PRETHERAP?+PRE(1W)(DIAGNO?+TREATMENT?+THERAP?)
S17	ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+CTHA+CTAP+CT/AB+CT/TI+TOMOGRA?+MDCT+NMR+MRI+SPECT+PE
S18	S15*S16*S17
S19	S15*S12/TI*S17/TI
S20	S18+S19

CQ14	腎機能および肝機能低下患者における肝腫瘍の診断には，どの検査法が有用か？
[MEDLINE]	
S1	(LIVER+HEPATIC?+HEPATO?+KIDNEY+RENAL+CK+CREATIN?)(3N)(FUNCTION?+IMPAIR?+FAILUR?+INSUFFICIEN?+DETERIORA?+EXACERBAT?+DYSFUNCT?+HYPOFUNCT?+LESION?+DISORDER?+DAMAGE?+ABNORMAL?)
S2	NEPHROPATH? OR CIRRHO? OR NEPHRITI?
S3	JAUNDIC? OR HYPERBIL? OR (BIL OR BILI?)(3N)(RISE? OR RISING? OR ELEVAT? OR HIGH? OR INCREAS?)
S4	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S5	GD()EOB()DTPA+GADOXETIC?(3W)ENHANCE?(3W)(MRI OR MR)
S6	CONTRAST?(3W)(CT OR MR OR NMR OR MRI OR ULTRASON?)
S7	CTAP OR CTHA OR IODI?(3N)CONTRAST? OR GD OR GADOXETIC? OR DTPA OR EOB OR SONAZOID?
S8	CONTRAST?(3W)ENHANC? OR ENHANC?(3N)(CT OR MR OR NMR OR MRI OR ULTRASON?)
S9	(DI+DIAGNOSIS!+RA+RI+US)/DF
S10	(S1+S2+S3+S4)*S5/TI
S11	(S1+S2+S3)*S4*(S5+S6+S7+S8)/TI
S12	(HEPATIC? OR HEPATO? OR LIVER? OR S1+S2+S3)/TI AND S11
S13	S12*S9
S14	S13+S10
S15	S14/HUMAN+(S14 NOT ANIMALS)
S16	S15 AND PY=>1982 AND UP=19830906:20111231
S17	S16/ENG
S18	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S19	S17 NOT S18
S20	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S21	S17*S20
S22	S19+S21

CQ15	肝細胞癌の画像診断において，どのように造影剤を用いるべきか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?
S6	ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF
S7	CONTRAST MEDIA!+(CONTRAST+RADIOPAQUE)(1N)(MEDIA?+DYE?+MATERIAL?+AGENT?)
S8	SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC
S9	S4*(S5+S6)*S7
S10	S8*S9
S11	(CONTRAST? OR IODINE? OR GD)/TI AND S9
S12	S10+S11

CQ16	肝細胞癌の病期診断に頭部MRI，胸部CT，骨シンチグラフィー，FDG-PETは必要か？
[MEDLINE]	

S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:20111231
S5	DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?
S6	ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF
S7	STAGE? OR STAGING? OR METASTA? OR INFILTRA? OR INVASI? OR INVOLVE?
S8	S4*(S5+S6)*S7
S9	CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING? OR DETECT? OR DIAGNOS?
S10	S8*(S7/TI+S9/TI)*(HEPATO? OR HEPATIC? OR LIVER?)/TI
S11	S10*(S7/TI+DETECT?/TI+DIAGNO?/TI)
S12	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S13	S11 NOT S12
S14	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S15	S11*S14
S16	S15+S13

CQ17	造影超音波は，肝細胞癌における診断能を改善するか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF
S18	CONTRAST MEDIA! + (CONTRAST + RADIOPAQUE)(1N)(MEDIA? + DYE? + MATERIAL? + AGENT?
S19	(DI OR DIAGNOSIS! OR RA OR RI OR US)/DF OR DIAGNOS?/TI
S20	S16*S17*S18*S19
S21	S20*S19/MAJ
S22	S21*S17/MAJ

CQ18	造影超音波は，局所療法やTACEの治療効果判定に有用か？

[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DF+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DF+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DF
S2	(CLINICAL+CRITICAL+TREATMENT?+CARE)(2N)(PATH+PATHS+PATHWAY?+PROTOCOL?+PLANNING?+GOOD(2W)PRACTICE?)/TI
S3	(SYSTEMATIC+QUANTITATIVE+METHODOLOGIC+COLLABORATIVE+INTEGRATIVE)(1W)(REVIEW?+OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
S4	DT=META-ANALYSIS+META-ANALYSIS/DF +(META()ANALY?+METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DF+RANDOM ALLOCATION/DF+RANDOM?+DOUBLE-BLIND METHOD/DF+SINGLE-BLIND METHOD/DF+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DF+SINGLE-BLIND METHOD/DF+CROSS-OVER STUDIES/DF+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/ID+CONTROL?(1W)(TRIAL?+STUD?)+PLACEBO?/TI
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!+(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+COHORT?/TI
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DF+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DF+CASE()(CONTROL+COMPARISON?+REFERENT?+REFERRENT?)/TI+RETROSPECTI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF
S18	(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)
S19	(LOCAL+TOPICAL)(3N)(REMED?+THERAP?+TREATMENT?)
S20	(BENEFIT?+EFFECT?+EFFIC?+GAIN?+PERFORMANCE?+ACTION?)(1N)(TREATMENT?+THERAP?+CURATIVE?)
S21	S16*S17*(S18+S19)*S20
S22	S16*S17*(S18+S19)
S23	S15*S17*(S18+S19)*S20

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第3章	手　術

第1節	手術適応・術式
CQ19	肝切除術を行う際の術前肝機能評価因子は何を用いるのが適当か？ また肝機能面からみた手術適応は？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3*UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	S4 NOT S5
S7	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S8	S4*S7
S9	S6+S8
S10	(HCC+LIVER+HEPAT?+NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
S11	HEPATECTOM?
S12	S9 AND (S10 OR S11)
S13	PREOPERAT?+PRESURGER?+(BEFORE+PRE+PRIOR)(W)(OPERAT?+SURGER?)
S14	PREDICT?/DE AND SURGERY/DE
S15	S13+S14
S16	S15(3N)(ASSESSMENT? OR TEST? ?)
S17	S15 AND (HEPAT? OR LIVER)(3N)(FUNCTION? OR STATUS?)
S18	S12 AND (S16 OR S17)

CQ20	標準的な肝切除術式とは？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:20111231
S5	LIVER NEOPLASMS!(L)SU
S6	HEPATECTOMY!
S7	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI
S8	(NEW? OR STANDARD? OR GOLDSTANDARD? OR APPROACH? OR METHOD? OR TECHNI?)/TI
S9	HEPATECTOMY!(L)METHODS
S10	(S5+S6)*S7*S8
S11	(SEGMENT? OR SUBSEGMENT?)/TI*(S5+S6)*S8
S12	S4*(S9+S10+S11)

CQ21	腫瘍条件からみた肝切除の適応は？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630

S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	HEPATECTOMY!
S16	LIVER NEOPLASMS(L)SU
S17	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI
S18	(INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S19	(EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S20	INDICAT?/TI+INDICAT?(3N)(SURGER?+SURGIC?+RESECT?+OPERAT?+HEPATECTOM?)
S21	S14*(S15+S16+17)*(S18+S19+S20)
S22	S21*UP=20070701:20111231

第2節	予後因子
CQ22	肝切除後の予後因子は何か？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	(HCC+LIVER+HEPAT?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
S18	HEPATECTOM?
S19	S16 AND (S17 OR S18)
S20	(PREDICT? OR PROGNOS?)(N)(FACTOR? OR VARIABL?)
S21	S19 AND S20
S22	S21 AND (CARCINOMA, HEPATOCELLULAR!)/MAJ

CQ23	切除断端距離は予後に寄与するか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT

S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	(HCC+LIVER+HEPAT?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
S18	HEPATECTOM?
S19	S16 AND (S17 OR S18)
S20	SPECIM? OR SAMPL? OR TISSUE OR ORGANIZATION? OR MARGIN?
S21	PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S22	S19 AND S20 AND S21
S23	S22 AND (CARCINOMA, HEPATOCELLULAR!)/MAJ

CQ24	**系統的切除は予後に寄与するか？**
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	(ANATOMI?+SYSTEMIC?+SYSTEMATIC?)(4N)(RESECT?+HEPATECTOM?+SURGER?+SURGICA?+OPERATI?)
S18	PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S19	S16*S17*S18

第3節	周術期管理
CQ25	周術期の血液製剤の積極的な投与は推奨されるか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S12 NOT ANIMALS)
S3	S2/ENG
S4	S3*UP=20070701:20111231
S5	SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S6	PERIOPERAT?+INTRAOPERAT?+(PERI+INTRA+DURING?)(3N)(OP+SURGER???+OPERAT?+HEPATECTOM?+RESECT?)
S7	BLOOD TRANSFUSION! OR (BLOOD? OR ERYTHROCY? OR RED()CELL? ? OR PLASMA?)(3N)TRANSFUS? OR FROZEN?(3N)PLASMA?
S8	BLOOD()(DERIVATIVE?+PREPARATION?+PRODUCT?+FORMUL?)+(HEMATOLOGIC?+HEMOPOIETIC?+HEMATOPOIETIC?)(2W)(DRUG? ?+AGENT? ?+FORMUL?)
S9	S4*S5*S6*(S7+S8)

CQ26	肝流入血流遮断や中心静脈圧低下は，肝切離中出血量を減少させるか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	S11/HUMAN+(S11 NOT ANIMALS)
S13	S12/ENG
S14	S13*UP=20070701:20111231
S15	SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S16	BLOOD LOSS, SURGICAL!+BLOOD()LOSS?+(HEMORRHAGE?+BLEED?+HAEMORRHAG?)(3N)(OP+SURGIC?+SURGER???+OPERAT?+HEPATECTOM?+RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT

S17	S14*S15*S16
S18	PEDICL?(1W)(CLAMP?+OCCLUS?)+IPO+HPC+PRINGL?
S19	((CENTRAL?(1W)VENOUS?(1W)PRESSUR?)+CVP)(3N)(REDUC?+LOW+DECREAS?+FALL??+DROP???)
S20	S17*(S18+S19)
S21	PEDICL?(1W)(CLAMP?+OCCLUS?)+IPO+HPC+PRINGL?+PORTAL()TRIAD()CLAMP?+PTC
S22	S17*(S19+S21)

CQ27	肝切除において腹腔ドレーン留置は必要か？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	S11/HUMAN+(S12 NOT ANIMALS)
S13	S12/ENG
S14	S13 AND PY=>1982 AND UP=19830906:20111231
S15	SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S16	ABDOM?(2N)DRAIN?
S17	S14*S15*S16

第4節	補助療法
CQ28	術前補助化学療法は肝切除後の予後を改善するか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S18	NEOADJUVANT?+NAC+NEO()ADJUVAN?
S19	(PREOPERAT?+(BEFORE+PRE)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))(4N)(CHEMOEMB?+EMBOL?+CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)
S20	(CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!)*(PREOPERAT?+(BEFORE+PRE)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT
S21	S16*S17*(S18+S19+S20)
S22	PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S23	S21*S22

CQ29	術後補助化学療法は肝切除後の予後を改善するか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14*UP=20070701:20111231
S16	S11*S15
S17	SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
S18	CHEMOTHERAPY, ADJUVANT!+ADJUVANT?(3N)CHEMOTHER?
S19	(POSTOPERAT?+(AFTER+FOLLOW?)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))(4N)(CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)
S20	(CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!)*(POSTOPERAT?+(AFTER+FOLLOW?)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))
S21	S16*S17*(S18+S19+S20)

S22	PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S23	S21*S22

第5節	肝移植
CQ30	肝移植前のダウンステージングは肝移植の予後を改善するか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	S4 NOT S5
S7	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S8	S4*S7
S9	S6+S8
S10	LIVER TRANSPLANTATION! OR LIVER!(L)TR OR TRANSPLAN?
S11	DOWN?()STAG? OR DOWNSTAG?
S12	S9*S10*S11
S13	PRE()TRANSPLAN? OR PRETRANSPLAN? OR TRANSPLAN?(3N)(BEFOR? OR FOLLOW? OR AFTER? OR WAIT?)
S14	BRIDGING? OR ABLAT? OR RFA
S15	(LOCAL?+LOCOREGION?+LOCO()REGION?+TOPICAL? OR BRIDG?)(3N)(THERAP?+TREAT?)
S16	TAE OR TACE OR (TRANSCATHETER? OR TRANSARTER?)(3N)(EMBOLI? OR CHEMOEMBOLI?)
S17	S13(5N)(S14+S15+S16)
S18	S9*S17
S19	S12+S18

CQ31	肝細胞癌に対する肝移植の適応基準は何か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	S4 NOT S5
S7	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S8	S4*S7
S9	S6+S8
S10	LIVER TRANSPLANTATION! OR LIVER!(L)TR OR TRANSPLAN?
S11	LIVER TRANSPLANTATION!(L)UT OR TRANSPLANT?(3N)UTILIZ?
S12	(INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(4N)TRANSPLANT?
S13	CRITERI?(4N)S12
S14	S9*S11
S15	S9*S13
S16	S9*S12
S17	S9*TRANSPLAN?/TI*(CRITERI?+PRIORIT?)
S18	S14+S15+S16+S17

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第4章	穿刺局所療法

CQ32	穿刺局所療法はどのような患者に行うべきか？
CQ33	各穿刺局所療法の選択は，どのように行うべきか？
CQ34	穿刺局所療法にTACEを併用することで予後を改善できるか？
CQ35	造影超音波，CTやMRIとのfusion imageは局所療法の治療ガイドとして有用か？
[PubMed]	
#1	("carcinoma, hepatocellular" [MH] OR "HCC" [tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency" [tiab] OR "RFA"[tiab] OR "RFTA" OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND 2007/7/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	("carcinoma, hepatocellular" [MH] OR "HCC" [tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency" [tiab] OR "RFA"[tiab] OR "RFTA" OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND 2007/7/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND Eng[la] NOT "case reports"[pt]
#3	#1 or #2

CQ36	局所療法の効果判定に有用な画像診断は何か？
[PubMed]	
#1	("carcinoma, hepatocellular" [MH] OR "HCC" [tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency" [tiab] OR "RFA"[tiab] OR "RFTA" OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND ("MRI"[tiab] OR "CT"[tiab] OR ultraso*[tiab]) 1982/1/1:2011/11/15[dp] AND Eng[la] NOT "case reports"[pt]
#2	("carcinoma, hepatocellular" [MH] OR "HCC" [tiab]) AND ("Ethanol Injection"[tiab] OR "Ablation"[tiab] OR "Ablative"[tiab] OR "Thermal Ablation"[tiab] OR "radiofrequency" [tiab] OR "RFA"[tiab] OR "RFTA" OR "PEI"[tiab] OR "PEIT"[tiab] OR "Ethanol/administration and dosage"[MH] OR "Injections, Intralesional"[MH] OR "microwave"[tiab]) AND ("MRI"[tiab] OR "CT"[tiab] OR ultraso*[tiab]) 1982/1/1:2011/12/31[dp] AND 2011/11/16:2012/3/30[MHDA] AND
#3	#1 or #2

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第5章	肝動脈化学塞栓療法(TACE)

CQ37	どのような症例がTACE／TAEのよい適応か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	S4 NOT S5
S7	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S8	S4*S7
S9	S6+S8
S10	(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?)
S11	(INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S12	(EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S13	INDICAT?/TI+INDICAT?(3N)(ETHANOL?+RFA+PEI+PMCT+ABLAT?)
S14	S9*S10*(S11:S13)

CQ38	TACE／TAEにおいて塞栓物質や抗癌剤は何を用いるべきか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	S4 NOT S5
S7	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S8	S4*S7
S9	S6+S8
S10	(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+TAE+TACE
S11	((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)
S12	CHEMOEMBOLIZATION, THERAPEUTIC!
S13	S9*(S10+S11+S12)
S14	AD/DE+TU/DE
S15	ANTINEOPLASTIC AGENTS!(L)(TU+AD)
S16	S13*(S14+S15)
S17	TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI?
S18	SUSPENS? OR MICROSPHE? OR OIL? ? OR CARRIER? OR BEAD? ? OR MATERIAL? OR AGENT? ? OR DRUG? ? OR COMPOUND? ? OR EMULS?
S19	S9*S17/TI*S18/TI
S20	S17/TI*S16
S21	S20*S18/DE
S22	S19+S21

CQ39	再TACE／TAEの時期の選択は？
[MEDLINE]	

S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	S4 NOT S5
S7	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S8	S4*S7
S9	S6+S8
S10	(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+TAE+TACE
S11	((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)
S12	CHEMOEMBOLIZATION, THERAPEUTIC! OR CHEMOTHERAPY, ADJUVANT!
S13	S9*(S10+S11+S12)
S14	RETRI?+RE()TRI???+RETRY?+RE()TRY?+TRY()AGAIN?+REPERFORM?+RE()PERFORM?
S15	ANOTHER?+REPEAT?+ADDITION?+SUPPLEMENT?+TWICE?+TWO()TIMES?+RETREATMENT?+RE()TREATMENT?+AGAIN?
S16	SECOND? OR 2ND
S17	RETHERAP? OR REAPPROACH? OR RE()(THERAP? OR APPROACH?)
S18	REEMBOLI? OR RECHEMOEMBOLI? OR RETRANSCATHE? OR RETRANSARTER?
S19	RETACE? OR RETAE OR RETRANSANTITHROMBO?
S20	RE()(TACE OR TAE OR ANTITHROMBO? OR ANTI()THROMBO?) OR REANTITHROMBO?
S21	S13*(S14+S15+S16+S17+S18)/TI
S22	TIME? OR TIMING? OR PERIOD? OR INTERVAL? OR OCCASION? OR POINT?
S23	S13*S18
S24	S13*(S14+S15+S16+S17+S18)
S25	S24*S22
S26	(S14+S15+S16+S17)(4N)(TACE OR TAE OR TRANSCATHE? OR TRANSARTE? OR EMBOLI? OR CHEMOEMBOLI? OR TREAT? OR THERAP?)
S27	S26*S24
S28	TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI? OR TAE OR
S29	(S27+S25)*S28/TI
S30	S29+S21

CQ40	**TACEの効果判定に有用な画像診断は何か？**
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+TAE+TACE
S16	((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)
S17	CHEMOEMBOLIZATION, THERAPEUTIC!
S18	S14*(S15+S16+S17)
S19	(S15 OR CHEMOEMBOLI? OR CHEMOINFU? OR LOCOREGIONAL?()THERAP?)/TI
S20	RA/DF OR US/DF OR RI/DF OR DIAGNOSTIC IMAGING! OR LIVER NEOPLASMS!(L)PA

S21	((TUMOR OR TUMOUR)()RESPONSE? OR INDICATOR? OR VISUALIZ? OR ASSESS? OR EVALUAT? OR THERAPEUTIC()EFFECT? OR IMAGING? OR FEATURE? OR FINDING? OR CT OR MR OR
S22	(USEFUL? OR EFFECTIVE? OR EFFICAC? OR BENEFIT?)/TI
S23	S18*S19*S20
S24	S23*(S21+S22)

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第6章	化学療法

CQ41	全身化学療法はどのような症例に行われるか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14 AND UP=20070701:20111231
S16	S11*S15
S17	DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?
S18	S16*S17
S19	S17/TI AND S18
S20	DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS!(L)(TU+AD)
S21	S18*S20
S22	S20/MAJ AND S21
S23	S22+S19
S24	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S25	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S26	S23 NOT S24
S27	S23*S25
S28	S26+S27

CQ42	肝動注化学療法は予後を改善するか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S7	S4 NOT S5
S8	S4*S6
S9	S7+S8
S10	DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?
S11	S9*S10
S12	HAI+(INTRAARTER?+ARTER?)(3N)(ADMINISTR?+DOSE?+DOSING?+INFUS?+INJECT?)
S13	(INTRAARTER? OR ARTER?)(3N)(THERAP? OR CHEMOTHERAP? OR TREAT?)
S14	PROGNOSIS!+PROGNOS?+OUTCOME?+SURVIV?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S15	S11*(S12+13)*S14

CQ43	**化学療法(薬物療法)で有効な治療は何か？**
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA?? +HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S13	S12/HUMAN+(S12 NOT ANIMALS)
S14	S13/ENG
S15	S14 AND UP=20070701:20111231
S16	S11*S15
S17	DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?
S18	DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS!(L)(TU+AD)
S19	S16*(S17/TI+S18/MAJ)
S20	S19*S12/TI
S21	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S22	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S23	S20 NOT S21
S24	S20*S22
S25	S23+S24

CQ44	**ホルモン療法は有効か？**
[MEDLINE]	

S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S7	S4 NOT S5
S8	S4*S6
S9	S7+S8
S10	GONADOTROPIN-RELEASING HORMONE!+(LUTEINI?+GONADOTROPIN?)(3N)RELEAS?(2N)HORMON?(2N)(AGONIST?+ANALOG?)+LH(1W)RH+LHRH+GONADORELIN?+(GNRH+LHRH+(GN+LH)(1W)RH)(W)(AGONIST?+ANALOGUE?)+BUSERELIN?+GOSERELIN?+LEUPROLI?+NAFARELIN?+TRIPTORELIN?
S11	AROMATASE INHIBITORS!+AROMATAS?(2N)INHIBIT?+AMINOGLUTETHIMID?+TESTOLACTON?+FADROZOL?+ANASTROZOL?+LETROZOL?+EXEMESTAN?
S12	TAMOXIFEN?+ADOPAN+EMALOOK+SOSHIGEN+TASUOMIN+NORXIFEN+NOLVADEX+PANLEEF+PHENOLURN+RESPOL+ICI(1W)46474+ICI46474+ICI(1W)47699+ICI47699+ZITAZONIUM
S13	S10:S12
S14	S9*S13

CQ45	化学療法(薬物療法)の治療効果予測因子・予後因子は何か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND UP=20070701:20111231
S5	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S6	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S7	S4 NOT S5
S8	S4*S6
S9	S7+S8
S10	(PROGNOS? + PREDICT?)(1W)(FACTOR? + VARIABLE? + INDEX +INDIC?)+PREDICTOR?
S11	S9*S10
S12	(BENEFIT? +EFFECT? + EFFIC? + GAIN? + PERFORMANCE? + ACTION?+RESPON?+OUTCOM?)(3N)(CHEMOTHER?+CHEMORADIOTHER?+TREATMENT? + THERAP? + CURATIVE?)
S13	S11*S12
S14	DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?
S15	S13*S14

CQ46	化学療法の治療効果判定はどのようにするか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S12	S9 NOT S10
S13	S9*S11
S14	S12+S13
S15	DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?
S16	RESPON?(2N)(CRITERIA?+EVALUAT?)
S17	S14*S15*S16

CQ47	**化学療法の副作用とその対策は何か？**
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S11	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S12	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S13	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S14	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S15	DT=META-ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS
S16	S9 NOT S14
S17	S9*S15
S18	S16+S17
S19	DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?
S20	ANTINEOPLASTIC AGENTS!(L)(AE+PO+CT+TO)
S21	(ADVERS?+SAFETY+TOXIC?)/TI
S22	(ADVERS?+SAFETY+TOXIC?)(2N)(MANAG?+PROPHYLAX?+PREVEN?)
S23	S18*S19
S24	S23*S21+S23*S22*S20+S20*(S10:S13)*S23

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第7章	放射線治療

CQ48	肝細胞癌に対する，3次元原体照射法による放射線治療は有用か？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC +HCCS)/TI*LIVER NEOPLASMS!
S13	S11*S12
S14	S13/HUMAN OR (S13 NOT ANIMALS)
S15	S14/ENG
S16	S15 AND UP=20070701:20111231
S17	RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
S18	S16*S17
S19	PROGNOSIS!+PROGNOS?+OUTCOME?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S20	EFFECACY OR SURVIVAL? OR RESPONSE()(RATE OR RATES) OR LOCAL()CONTROL? OR SAFETY OR ADVERS?(1W)(EFFECT? OR EVENT OR EVENTS) OR TOXICITY OR FEASIBILITY
S21	S19+S20
S22	S18*S21

CQ49	肝細胞癌に対する，体幹部定位放射線治療は有用か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	STEREOTACTIC(3N)(RADIOTHERAP? OR RADIOSURG? OR RADIATION? OR IRRADIAT?)
S3	RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
S4	SBRT OR SBT OR SRT OR STEREOTACTIC OR PINPOINT?
S5	DT=REVIEW?
S6	S1 NOT S5
S7	S6/HUMAN+(S6 NOT ANIMALS)
S8	S7/ENG
S9	S8 AND PY=>1982 AND UP=19830906:19900630
S10	S8 AND PY=>1982 AND UP=19900630:19950630
S11	S8 AND PY=>1982 AND UP=19950630:20000630
S12	S8 AND PY=>1982 AND UP=20000630:20050630
S13	S8 AND PY=>1982 AND UP=20050630:20111231

S14	S9:S13
S15	S14*S2
S16	S14*S3*S4
S17	S15+S16

CQ50	肝細胞癌に対する，粒子線治療〔陽子線治療，重粒子(炭素イオン)線治療〕は有用か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA??+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	(HEAVY OR CARBON? OR PROTON? OR PARTICL?)(2N)(THERAP? OR ION OR IONS OR BEAM OR BEAMS OR IRRADIAT? OR RADIOISOTOP?)
S3	RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
S4	DT=REVIEW?
S5	S1 NOT S4
S6	S5/HUMAN+(S5 NOT ANIMALS)
S7	S6/ENG
S8	S7 AND PY=>1982 AND UP=19830906:19900630
S9	S7 AND PY=>1982 AND UP=19900630:19950630
S10	S7 AND PY=>1982 AND UP=19950630:20000630
S11	S7 AND PY=>1982 AND UP=20000630:20050630
S12	S7 AND PY=>1982 AND UP=20050630:20111231
S13	S8:S12
S14	S13*S2*S3

CQ51	肝細胞癌の遠隔転移に対しては，放射線治療が適応となるか？
[MEDLINE]	
S1	DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES + PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT
S2	(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI
S3	(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB + ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP
S4	DT=META-ANALYSIS+META-ANALYSIS/DE +(META()ANALY? + METAANAL?)/TI
S5	DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)
S6	DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL? + STUD?)
S7	DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI
S8	COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!
S9	DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI
S10	CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE()CONTROL/TI
S11	S1:S10
S12	CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC +HCCS)/TI*LIVER NEOPLASMS!
S13	S11*S12
S14	S13/HUMAN OR (S13 NOT ANIMALS)
S15	S14/ENG
S16	S15 AND UP=20070701:20111231
S17	RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
S18	S16*S17
S19	PROGNOSIS!+PROGNOS?+OUTCOME?+RECURRENCE?+RELAPSE?+REOCCURRENCE?
S20	EFFECACY OR SURVIVAL? OR RESPONSE()(RATE OR RATES) OR LOCAL()CONTROL? OR SAFETY OR ADVERS?(1W)(EFFECT? OR EVENT OR EVENTS) OR TOXICITY OR FEASIBILITY
S21	S19+S20

S22	S18*S21
S23	S1:S6
S24	S23/HUMAN OR (S23 NOT ANIMALS)
S25	S24/ENG
S26	S25 AND UP=20070701:20111231
S27	(RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?)*METASTA?
S28	S16*S27
S29	S26*S27
S30	METASTA?(4N)(RADIOTHER?+CHEMORADIO?+RADIOCHEM?+IRRADIAT?+RADIAT?+BRACHYTHER?+RADIOSURG?)
S31	S16*S30
S32	S26*S30
S33	CENTRAL NERVOUS SYSTEM NEOPLASMS!(L)SECONDARY OR BONE
S34	(BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?)(4N)METASTA?
S35	S28+S31
S36	(S29+S32)*(S33+S34)
S37	(BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?)/TI AND S36
S38	S35+S37
S39	S34/TI AND S36
S40	S39+S35

対象データ：2007年7月1日～2011年12月31日（※新設されたCQについては，1982年1月1日～2011年12月31日で検索）
疾患：肝細胞癌に限定（動物実験を除く）
言語：英語・日本語文献に限定

第8章	治療後のサーベイラインス，再発予防，再発治療

CQ52	肝切除後や穿刺局所療法後，どのようにフォローアップするか？
(1)	肝切除後，どのようにフォローアップするか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	HEPATECTOMY!
S16	LIVER NEOPLASMS(L)SU
S17	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI
S18	FOLLOWUP OR FOLLOW()UP
S19	S14*(S15+S16+S17)
S20	S18*S19
S21	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)(4N)(AFTER OR
S22	POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST()(SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)
S23	S18/TI*S19
S24	S18(3N)(EVALUAT? OR ASSESS? OR INVESTIGAT? OR METHOD? OR SYSTEM? OR ADEQUAT? OR APPROPRIAT? OR OPTIMAL? OR RECOMMEND?)
S25	(S21+S22)(4N)S18
S26	S20*S24
S27	S20*S25
S28	(S26+S27)*(S21+S22)/TI+S23

CQ52	肝切除後や穿刺局所療法後，どのようにフォローアップするか？
(2)	穿刺局所療法後，どのようにフォローアップするか？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10

S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	(PEI OR PEIT OR EIT) AND ETHANOL??
S16	MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)
S17	(PMCT OR MCT) AND MICROWAVE?
S18	ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?
S19	RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA
S20	PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL? OR ETHYL()ALCOHOL?)
S21	PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?
S22	RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLAT?
S23	(LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO()REGIONAL?)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)
S24	S15:S23
S25	S14*S24
S26	FOLLOWUP OR FOLLOW()UP
S27	S25*S26
S28	S26/TI*S27
S29	S26(3N)(EVALUAT? OR ASSESS? OR INVESTIGAT? OR METHOD? OR SYSTEM? OR ADEQUAT? OR APPROPRIAT? OR OPTIMAL? OR RECOMMEND?)
S30	(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR
S31	S29*S27
S32	S30*S27
S33	S28+S31+S32
S34	POST()(RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL? OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)
S35	S33*(S34+S24/TI)

CQ53	**肝切除後や穿刺局所療法後の有効な再発予防法は何か？**
(1)	**肝切除後の有効な再発予防法は何か？**
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	HEPATECTOMY!
S16	LIVER NEOPLASMS(L)SU
S17	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI
S18	RECURREN?
S19	NEOPLASM RECURRENCE, LOCAL!(L)PC
S20	(PROGRES? OR RECURREN?)(3N)(PREVEN? OR PROPHYLA?)
S21	S14*(S15+S16+S17)*S18
S22	S21*(S19+S20)
S23	(S18/TI+S17) AND S22
S24	(PREVEN? OR PROPHYL? OR REDUC? OR DECREAS?)/TI AND S22

S25	S23+S24

CQ53	肝切除後や穿刺局所療法後の有効な再発予防法は何か？
(2)	穿刺局所療法後の有効な再発予防法は何か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	(PEI OR PEIT OR EIT) AND ETHANOL??
S16	MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)
S17	(PMCT OR MCT) AND MICROWAVE?
S18	ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?
S19	RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA
S20	PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL? OR ETHYL()ALCOHOL?)
S21	PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?
S22	RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLAT?
S23	(LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO()REGIONAL?)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)
S24	S15:S23
S25	RECURREN?
S26	NEOPLASM RECURRENCE, LOCAL!(L)PC
S27	(PROGRES? OR RECURREN?)(3N)(PREVEN? OR PROPHYLA?)
S28	S14*S24*S25
S29	S28*(S26+S27)
S30	SURVIV?(3N)(INCREAS? OR PROLONG? OR IMPROV?)
S31	(PREDICT? OR DETECT?)(3N)(PROGRES? OR RECURREN?)
S32	USEFUL? OR EFFECTIVE? OR EFFICAC?
S33	S28*S30
S34	S28*S31
S35	TREATMENT OUTCOME/DE
S36	(S33+S34)*(S32+S35)
S37	S36*(S24/TI OR S25/TI OR PROVEN? OR PROPHYL? OR REDUC? OR S30/TI)
S38	S29+S37
S39	(S24/TI OR MT/DE OR TU/DE OR S24/MAJ) AND S38

CQ54	肝移植後の有効な再発予防法は何か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630

S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	LIVER TRANSPLANTATION! OR LIVER!(L)TR OR LIVER?(3N)TRANSPLANT?
S16	RECURREN?
S17	NEOPLASM RECURRENCE, LOCAL(L)PC
S18	(PROGRES? OR RECURREN?)(3N)(PREVEN? OR PROPHYLA?)
S19	IMMUNOSUPPRESSIVE AGENTS!(L)TU
S20	SURVIV?(3N)(INCREAS? OR PROLONG? OR IMPROV?)
S21	(PREDICT? OR DETECT?)(3N)(PROGRES? OR RECURREN?)
S22	USEFUL? OR EFFECTIVE? OR EFFICAC?
S23	TREATMENT OUTCOME/DE
S24	S14*S15*S16
S25	S24*(S17+S18)
S26	S24*(S19+S20+S21)
S27	S26*(S22+S23+S20/TI)
S28	S25+S27
S29	LIVER TRANSPLANTATION!/MAJ OR LIVER TRANSPLANTATION!(L)MT OR TRANSPLANT?/TI
S30	S29*S28

CQ55	肝切除後の再発に対する有効な治療は何か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	HEPATECTOMY!
S16	LIVER NEOPLASMS(L)SU
S17	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI
S18	(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)(4N)(AFTER OR
S19	POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST()(SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)
S20	(S18+S19)(4N)RECURREN?
S21	S14*(S15+S16+S17)
S22	S20*S21
S23	NEOPLASM RECURRENCE, LOCAL!(L)(TH+DT+RT+SU)
S24	S22*S23
S25	S20/TI*S22
S26	(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI

S27	S26 AND S25
S28	(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(5N)S20
S29	S25*S28
S30	RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!
S31	TU/DE
S32	S25*S30*S31
S33	S24*S20/TI
S34	S24+S27+S29+S32+S33

CQ56	**穿刺局所療法後の再発に対する有効な治療法は何か？**
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	(PEI OR PEIT OR EIT) AND ETHANOL??
S16	MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)
S17	(PMCT OR MCT) AND MICROWAVE?
S18	ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?
S19	RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA
S20	PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL? OR ETHYL()ALCOHOL?)
S21	PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?
S22	RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLAT?
S23	(LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO()REGIONAL?)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)
S24	S15:S23
S25	S14*S24
S26	(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?)(4N)(AFTER OR FOLLOW?)
S27	POST()(RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL? OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)
S28	(S26+S27)(4N)RECURREN?
S29	NEOPLASM RECURRENCE, LOCAL!(L)(TH+DT+RT+SU)
S30	(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI
S31	S25*S28
S32	S29*S31
S33	S30*S31
S34	RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!
S35	TU/DE
S36	(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(4N)S28
S37	S31*S36
S38	S31*S34*S35

S39	(AFTER OR FOLLOW?)(1W)(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?)
S40	RECURREN?(3W)S39
S41	S40*S31*(S29+S30)
S42	S32+S33+S37+S38+S41

CQ57	肝移植後の再発に対する有効な治療法は何か？
[MEDLINE]	
S1	CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!
S2	S1/HUMAN+(S1 NOT ANIMALS)
S3	S2/ENG
S4	S3 AND PY=>1982 AND UP=19830906:19900630
S5	S3 AND PY=>1982 AND UP=19900630:19950630
S6	S3 AND PY=>1982 AND UP=19950630:20000630
S7	S3 AND PY=>1982 AND UP=20000630:20050630
S8	S3 AND PY=>1982 AND UP=20050630:20111231
S9	S4:S8
S10	DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI
S11	S9 NOT S10
S12	DT=META-ANALYSIS OR META ANALYSIS OR (META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13	S9*S12
S14	S11+S13
S15	LIVER TRANSPLANTATION! OR LIVER!(L)TR OR LIVER?(3N)TRANSPLANT?
S16	S14*S15
S17	NEOPLASM RECURRENCE, LOCAL!(L)(TH+DT+RT+SU)
S18	RECURREN?(4N)((FOLLOW? OR AFTER)(4N)TRANSPLAN? OR POSTTRANSPLAN? OR POST()TRANSPLAN?)
S19	S16*S17
S20	S16*S18/TI
S21	(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI
S22	S20 AND S21
S23	(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(5N)S18
S24	S23*S16
S25	RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!
S26	TU/DE
S27	S16*S25*S26
S28	S19+S22+S24+S27